arrow_back Back to App

Affordable Insulin During COVID-19: No Costs, Mail Order Access

This act aims to make insulin and related medical supplies more accessible for Medicare beneficiaries during the COVID-19 pandemic. It means patients will not have to pay any additional costs for insulin and injection supplies. Additionally, the act allows for ordering insulin and these supplies by mail, directly to their homes.
Key points
No extra costs: Medicare beneficiaries will pay nothing for insulin and injection supplies during the COVID-19 pandemic.
Mail order access: Ability to order insulin and related medical supplies by mail, making it easier to get medication without leaving home.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_2179
Sponsor: Rep. Waters, Maxine [D-CA-43]
Process start date: 2021-03-23
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable Insulin for the COVID–19 Emergency Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_2179.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-23.

What are the main provisions?

Key points include:

  • No extra costs: Medicare beneficiaries will pay nothing for insulin and injection supplies during the COVID-19 pandemic.
  • Mail order access: Ability to order insulin and related medical supplies by mail, making it easier to get medication without leaving home.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Waters, Maxine [D-CA-43].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

CATEGORIES

Health Benefits